drugset

drugset / Trial / NCT07489755

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

NCT07489755 ↗

Phase 3 Not yet recruiting 180 enrolled Shenzhen TargetRx Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs

Timeline

Start: 2026-04-01
Primary completion: 2030-05-01
Completion: 2031-05-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TGRX-678	Unknown	—	Oral

Indications